791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

• Hui Zhou,
• Jun Zhu,
• Xiaoling Li,
• Fei Li,
• Lei Fan,
• Lihong Liu,
• Zheng Zhao,
• Bing Chen,
• Qingyuan Zhang,
• Yuqin Song,
• Keshu Zhou,
• Chuan Jin,
• Zhengzi Qian,
• Ming Hou,
• Kaiyang Ding,
• Xiuhua Sun,
• Xianmin Song,
• Ming Jiang,
• Yu Hu,
• Ligen Liu,
• Hongwei Xue,
• Jun Luo,
• Bai He,
• Maxwell Wang

Affiliations

Hui Zhou

The Third Clinical Medical College, Zhejiang Chinese Medical University, Department of Neurobiology and Acupuncture Research, Hangzhou, China

Jun Zhu

1 Center for Global Health, Nanjing Medical University, Nanjing, Jiangsu, China

Xiaoling Li

10Liaoning Cancer Hospital and Institute, Shenyang, China

Fei Li

3 Xinlin College, Nantong University, Nantong, China

Lei Fan

6The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China

Lihong Liu

16The Fourth Hospital of Hebei Medical University, Hebei, China

Zheng Zhao

Third Department of Medical Oncology, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China

Bing Chen

11Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China

Qingyuan Zhang

2 Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China

Yuqin Song

1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China

Keshu Zhou

2The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan, China

Chuan Jin

3Cancer Hospital Affiliated to Guangzhou Medical University, Guangzhou, China

Zhengzi Qian

4Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Rese, Tianjin, China

Ming Hou

5Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Shandong University, Qilu, China

Kaiyang Ding

8The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

Xiuhua Sun

12Second Affiliated Hospital of Dalian Medical University, Dalian, China

Xianmin Song

13Shanghai First People’s Hospital, Shanghai Jiaotong University, Shanghai, China

Ming Jiang

14Cancer Center, West China Hospital, Sichuan University, Chengdu, China

Yu Hu

18Union Hospital, Tongji Medical College, Wuhan, China

Ligen Liu

20Shanghai Tongren Hospital, Shanghai, China

Hongwei Xue

21The Affiliated Hospital of Qingdao University, Qingdao, China

Jun Luo

22The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Bai He

23The First People’s Hospital of Changzhou, Changzhou, China

Maxwell Wang

24Akeso Biopharma Inc, Potomac, Maryland, USA